Drug intelligence / Profile preview

MK-1972

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral (based On Typical Administration In Early-phase Antiretroviral Trials; Not Explicitly Stated In Sources)

Overview

MK-1972 is a small molecule drug that was developed by Merck Sharp & Dohme for the treatment of HIV infections. It was investigated primarily as an antiretroviral agent in immune system diseases, infectious diseases, and urogenital diseases, with its main clinical focus on HIV-1 infection. The drug reached Phase 1 clinical trials but development was ultimately discontinued. The specific mechanism of action and molecular target for MK-1972 have not been publicly disclosed[1][2][3].

Beyond the preview

Go deeper on MK-1972.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-1972.

Explore the full profile